Genetic markers associated with cutaneous adverse drug reactions to allopurinol: aysystematic review

被引：2

作者：

Jarjour, Samantha ^{[1
]}

Barrette, Mathieu ^{[1
]}

Normand, Valerie ^{[2
]}

Rouleau, Jean Lucien ^{[3
,4
]}

Dube, Marie-Pierre ^{[2
,3
,4
]}

de Denus, Simon ^{[1
,2
,4
]}

机构：

[1] Univ Montreal, Fac Pharm, Montreal, PQ H3T 1J4, Canada

[2] Univ Montreal, Beaulieu Saucier Pharmacogen Ctr, Montreal, PQ, Canada

[3] Univ Montreal, Fac Med, Montreal, PQ, Canada

[4] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada

来源：

PHARMACOGENOMICS | 2015年 / 16卷 / 07期

关键词：

adverse reaction; allopurinol; drug-induced hypersensitivity syndrome; HLA; pharmacogenomics; rash; safety; Stevens-Johnson syndrome; toxic epidermal necrolysis; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; HAN CHINESE; HLA-B; HLA-B-ASTERISK-5801; ALLELE; RISK; POPULATION; GUIDELINES; THERAPY;

D O I：

10.2217/PGS.15.21

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenomic markers in the HLA coding genes have been associated with drug hypersensitivity of multiple drugs, including allopurinol. In this systematic review, we summarize the pharmacogenomic evidence available regarding allopurinol-induced cutaneous adverse drug reactions (cADRs). We found that the HLA-B*5801 allele was significantly associated with the risk of severe cADRs in the Han Chinese, Korean, Thai, Japanese and European populations. The association between less severe cADRs and HLA-B*5801 was less consistent. All SNPs identified in genome-wide association studies of common variants were also located in or nearby HLA-B*5801. Future studies should focus on more common but less severe allopurinol-induced cADRs, as well as the potential role of rare variants as predictors of these cADRs.

引用

页码：755 / 767

页数：13

共 50 条

[41] Pharmacogenetics of cutaneous adverse drug reactions
Aihara, Michiko
JOURNAL OF DERMATOLOGY, 2011, 38 (03): : 246 - 254
[42] Emerging Adverse Cutaneous Drug Reactions
Hagen, Joshua W.
Magro, Cynthia M.
Crowson, A. Neil
DERMATOLOGIC CLINICS, 2012, 30 (04) : 695 - +
[43] News on cutaneous adverse drug reactions
Vaillant, L
Machet, L
IMMUNOLOGIE CLINIQUE ET ALLERGOLOGIE ANTIBIOTIQUES: INTOLERANCE ET ALLERGIE, 2002, : 191 - 203
[44] Severe cutaneous adverse drug reactions
Chung, Wen-Hung
Wang, Chuang-Wei
Dao, Ro-Lan
JOURNAL OF DERMATOLOGY, 2016, 43 (07): : 758 - 766
[45] Cutaneous manifestations of adverse drug reactions
Beltrani, VS
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 1998, 18 (04) : 867 - +
[46] ADVERSE CUTANEOUS DRUG-REACTIONS
BORK, K
MEDIZINISCHE WELT, 1987, 38 (09): : 254 - 255
[47] Severe Cutaneous Adverse Drug Reactions
Schroeder, J.
DRUG SAFETY, 2013, 36 (09) : 942 - 942
[48] Cutaneous adverse drug reactions to cetirizine
Klos, K.
Kruszewski, J.
Chcialowski, A.
Slaweta, G.
ALLERGY, 2010, 65 : 254 - 254
[49] HLA-B*58:01 is not the only risk factor associated with allopurinol-induced severe cutaneous adverse drug reactions
Goncalo, Margarida
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
[50] ALLOPURINOL ASSOCIATED HYPERSENSITIVITY REACTIONS - CUTANEOUS AND RENAL MANIFESTATIONS
CHAN, HL
KU, G
KHOO, OT
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1977, 7 (05): : 518 - 522

← 1 2 3 4 5 →